11th Nov 2013 10:39
LONDON (Alliance News) - Physiomics PLC said Monday it has signed a collaboration agreement with the University of Oxford and the Oxford University Hospitals NHS trust for the development of its Virtual Tumour Clinical technology.
The technology is used in the prediction of optimal clinical regimens for cancer trials.
Under this agreement the Oxford University Hospitals trust will provide comparison and validation data for up to three clinical studies.
"Our development of Virtual Tumour Clinical is gathering pace," said Chief Executive Officer Mark Chadwick in a statement. "This collaboration represents another of what we hope will be a number of productive alliances between ourselves, academia and large pharma companies to maximise the predictive power of the technology."
Shares in the biotechnology company were trading up 2.9% at 0.175 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics